IL1B and breast carcinoma: Similarly, Tulotta et al. [46] using patient samples with stage II/III breast cancer, humanized mouse models of spontaneous breast cancer bone metastasis, genetic manipulation of breast cancer cells (MDA-MB-231-IL-1B+, T47D-IL-1B+ and MCF7-IL-1B+) and in vitro models (co-culture between HS5 or OB1 cells and MDA-MB-231 or T47D cells) demonstrated that not only the IL-1R antagonist, anakinra, but also the anti that a IL-1β antibody, canakinumab, inhibited breast tumor growth and progression to bone metastasis.